India, Aug. 8 -- GRAIL, Inc. (GRAL) announced that the U.S. FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on September 23, 2026 to review the company's Premarket Approval application for Galleri, its multi-cancer early detection (MCED) blood test.
Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers that currently lack recommended screening methods. When a cancer signal is identified, the test can predict its origin with high accuracy, helping guide further diagnostic evaluation. Importantly, Galleri is intended to complement, not replace, existing guideline-recommended screenings.
GRAIL emphasized the urg...